{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:27Z","timestamp":1792592427552,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to investigate the association between high-sensitivity C-reactive protein (hsCRP) levels and hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and assess its predictive efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study included 1,477 participants from the United States and 1,531 from China diagnosed with MASLD. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were assessed by vibration-controlled transient elastography (VCTE) to evaluate the presence and degree of hepatic fibrosis and steatosis. The relationship between hsCRP levels and hepatic fibrosis in MASLD patients was examined using multivariable-adjusted and restricted cubic spline (RCS) models. Additionally, subgroup analyses were conducted to investigate the potential heterogeneity among different characteristic subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results demonstrated a significant correlation between elevated hsCRP levels and an increased risk of significant fibrosis, advanced fibrosis, and cirrhosis in the US cohort of MASLD patients (OR 2.22, 1.69, and 2.85, respectively; all P &amp;lt;0.05). The results of the Chinese cohort were consistent with those of the US cohort, and there was a significant and positive correlation between hsCRP levels and the risk of hepatic fibrosis in patients with MASLD (OR 2.53, 3.85, and 3.78, respectively, all P &amp;lt;0.001). The RCS analysis revealed a significant non-linear relationship between hsCRP levels and the degree of hepatic fibrosis, with disparate inflection point values observed across different cohorts (approximately 9 mg\/L in the US cohort and 4 mg\/L in the Chinese cohort). The impact of hsCRP levels on the risk of hepatic fibrosis varied across different subgroups with distinct characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study demonstrated a significant correlation between hsCRP levels and the degree of hepatic fibrosis in patients with MASLD, with notable dose-response relationships and subgroup differences.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1544917","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T06:51:37Z","timestamp":1739170297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Yunfei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","author":"Younossi","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): A state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/nyas.v1538.1","article-title":"Metabolic dysfunction-associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications","volume":"1538","author":"Fan","year":"2024","journal-title":"Ann N Y Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.v44.10","article-title":"The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes","volume":"44","author":"Riley","year":"2024","journal-title":"Liver Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","article-title":"Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up","volume":"153","author":"Choe","year":"2024","journal-title":"Metabolism"},{"key":"B8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.958428","article-title":"Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2024.89635","article-title":"Management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"30","author":"Alkhouri","year":"2024","journal-title":"Am J Manag Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1684\/abc.2017.1232","article-title":"Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein","volume":"75","author":"Moutachakkir","year":"2017","journal-title":"Ann Biol Clin (Paris)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00943","article-title":"Evolution of C-reactive protein","volume":"10","author":"Pathak","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e3446","DOI":"10.1002\/dmrr.v37.8","article-title":"High-sensitivity C-reactive protein and risk of type 2 diabetes: A nationwide cohort study and updated meta-analysis","volume":"37","author":"Yang","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12986-021-00632-6","article-title":"Association between baseline and changes in high-sensitive C-reactive protein and metabolic syndrome: a nationwide cohort study and meta-analysis","volume":"19","author":"Xue","year":"2022","journal-title":"Nutr Metab (Lond)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12872-024-04091-8","article-title":"A linear positive association between high-sensitivity C-reactive protein and the prevalence of cardiovascular disease among individuals with diabetes","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-007-2060-x","article-title":"High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH","volume":"42","author":"Yoneda","year":"2007","journal-title":"J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"goad059","DOI":"10.1093\/gastro\/goad059","article-title":"Predicted pro-inflammatory hs-CRP score and non-alcoholic fatty liver disease","volume":"11","author":"Okekunle","year":"2023","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s41043-023-00372-8","article-title":"Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity","volume":"42","author":"Jamialahmadi","year":"2023","journal-title":"J Health Popul Nutr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.848937","article-title":"High-sensitive CRP correlates with the severity of liver steatosis and fibrosis in obese patients with metabolic dysfunction associated fatty liver disease","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101547","DOI":"10.1016\/j.eclinm.2022.101547","article-title":"Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"51","author":"Cao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108165","DOI":"10.1016\/j.pharmthera.2022.108165","article-title":"Transitional changes in the structure of C-reactive protein create highly pro-inflammatory molecules: Therapeutic implications for cardiovascular diseases","volume":"235","author":"Zeller","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.124.324248","article-title":"Shear-sensing by C-reactive protein: linking aortic stenosis and inflammation","volume":"135","author":"Zeller","year":"2024","journal-title":"Circ Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCULATIONAHA.113.007124","article-title":"Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy","volume":"130","author":"Thiele","year":"2014","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-116962","article-title":"Monomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomains","volume":"23","author":"Ji","year":"2009","journal-title":"FASEB J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14684","article-title":"Role of inflammatory markers in polycystic ovaries syndrome: In relation to insulin resistance","volume":"47","author":"Alissa","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/apt.v59.s1","article-title":"Pathogenesis of MASLD and MASH - role of insulin resistance and lipotoxicity","author":"Bansal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.06.004","article-title":"A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches","volume":"143","author":"Seki","year":"2012","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16272","article-title":"AMPK\/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression","volume":"38","author":"Marcondes-de-Castro","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00067","article-title":"Reactive oxygen species and oxidative stress in the pathogenesis of MAFLD","volume":"10","author":"Clare","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2016.06.003","article-title":"Non-alcoholic fatty liver and the gut microbiota","volume":"5","author":"Bashiardes","year":"2016","journal-title":"Mol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030550","article-title":"Double trouble: how microbiome dysbiosis and mitochondrial dysfunction drive non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Bahitham","year":"2024","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature04672","article-title":"Targeting C-reactive protein for the treatment of cardiovascular disease","volume":"440","author":"Pepys","year":"2006","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708101","article-title":"Case report: C-reactive protein apheresis in a patient with COVID-19 and fulminant CRP increase","volume":"12","author":"Ringel","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e935263","DOI":"10.12659\/AJCR.935263","article-title":"A report on the first 7 sequential patients treated within the C-reactive protein apheresis in COVID (CACOV) registry","volume":"23","author":"Schumann","year":"2022","journal-title":"Am J Case Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071956","article-title":"Seven COVID-19 patients treated with C-reactive protein (CRP) apheresis","volume":"11","author":"Esposito","year":"2022","journal-title":"J Clin Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e16236","DOI":"10.15252\/emmm.202216236","article-title":"A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein","volume":"15","author":"Zeller","year":"2023","journal-title":"EMBO Mol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T06:51:39Z","timestamp":1739170299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2025.1544917"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1544917","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"article-number":"1544917"}}